Total Payments
$928.21
2024 Payments
$249.97
Companies
14
Transactions
47
Medicare Patients
12,835
Medicare Billing
$642,328
Payment Breakdown by Category
Food & Beverage$928.21 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $928.21 | 47 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $275.89 | 12 | $0 (2024) |
| PFIZER INC. | $118.41 | 7 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $110.60 | 5 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $69.61 | 4 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $49.69 | 3 | $0 (2017) |
| Merck Sharp & Dohme LLC | $48.75 | 3 | $0 (2023) |
| Amgen Inc. | $46.15 | 2 | $0 (2024) |
| Astellas Pharma US Inc | $44.08 | 2 | $0 (2022) |
| Abbott Laboratories | $43.77 | 2 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $38.98 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $249.97 | 10 | Novartis Pharmaceuticals Corporation ($184.87) |
| 2023 | $157.73 | 9 | Merck Sharp & Dohme LLC ($48.75) |
| 2022 | $78.87 | 4 | PFIZER INC. ($23.69) |
| 2021 | $53.42 | 3 | Janssen Pharmaceuticals, Inc ($24.15) |
| 2020 | $35.52 | 2 | Boehringer Ingelheim Pharmaceuticals, Inc. ($21.96) |
| 2019 | $68.63 | 3 | Novartis Pharmaceuticals Corporation ($24.13) |
| 2018 | $72.02 | 4 | PFIZER INC. ($32.67) |
| 2017 | $212.05 | 12 | SANOFI-AVENTIS U.S. LLC ($49.69) |
All Payment Transactions
47 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $28.69 | General |
| Category: Cardiology | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.98 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/15/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $33.87 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/19/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $33.87 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/23/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $17.46 | General |
| Category: Cardiology | ||||||
| 06/10/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $32.16 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $32.16 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/27/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $27.44 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/27/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $1.39 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/20/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $15.75 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/13/2023 | Merck Sharp & Dohme LLC | BRIDION (Drug), VERQUVO, VERQUVO | Food and Beverage | In-kind items and services | $13.20 | General |
| Category: NEUROSCIENCE | ||||||
| 09/06/2023 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/20/2023 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $24.11 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 04/25/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.13 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/11/2023 | Merck Sharp & Dohme LLC | BRIDION (Drug), VERQUVO, VERQUVO | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: NEUROSCIENCE | ||||||
| 02/01/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $13.26 | General |
| Category: Cardio-renal | ||||||
| 01/24/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/17/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/02/2022 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $23.69 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/14/2022 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $14.98 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/30/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/26/2022 | Astellas Pharma US Inc | Lexiscan (Drug) | Food and Beverage | In-kind items and services | $21.72 | General |
| Category: Cardiology | ||||||
| 12/07/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 10/13/2021 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 31 | 3,878 | 4,706 | $756,442 | $162,726 |
| 2022 | 25 | 2,805 | 3,141 | $570,505 | $122,063 |
| 2021 | 25 | 3,090 | 3,622 | $1.2M | $195,731 |
| 2020 | 23 | 3,062 | 3,713 | $1.1M | $161,807 |
Total Patients
12,835
Total Services
15,182
Medicare Billing
$642,328
Procedure Codes
115
All Medicare Procedures & Services
115 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 284 | 327 | $79,788 | $21,837 | 27.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 183 | 213 | $76,254 | $20,947 | 27.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 114 | 115 | $64,824 | $17,341 | 26.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 183 | 232 | $55,680 | $15,084 | 27.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 238 | 239 | $134,722 | $12,744 | 9.5% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 1,488 | 1,951 | $54,628 | $11,907 | 21.8% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 28 | 29 | $38,069 | $11,484 | 30.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 88 | 90 | $40,680 | $9,637 | 23.7% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 597 | 610 | $59,780 | $6,530 | 10.9% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 20 | 28 | $5,431 | $4,258 | 78.4% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 39 | 59 | $10,422 | $3,831 | 36.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 29 | 29 | $15,718 | $3,314 | 21.1% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 18 | 63 | $8,692 | $2,637 | 30.3% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 14 | 45 | $6,750 | $2,470 | 36.6% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 42 | 42 | $9,870 | $2,366 | 24.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 23 | 24 | $8,232 | $2,317 | 28.1% |
| 99284 | Emergency department visit with moderate level of medical decision making | Facility | 2023 | 21 | 22 | $8,536 | $1,878 | 22.0% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 48 | 90 | $7,560 | $1,659 | 21.9% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 37 | 69 | $7,038 | $1,502 | 21.3% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 18 | 18 | $23,629 | $1,156 | 4.9% |
| 93308 | Ultrasound of heart, follow-up | Office | 2023 | 11 | 11 | $3,281 | $1,003 | 30.6% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 13 | 13 | $4,355 | $841.56 | 19.3% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2023 | 99 | 100 | $2,800 | $631.12 | 22.5% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 24 | 33 | $2,475 | $613.93 | 24.8% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 13 | 14 | $1,890 | $586.18 | 31.0% |
About Dr. Eric Ewald, MD
Dr. Eric Ewald, MD is a Cardiovascular Disease healthcare provider based in N Chelmsford, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1639126311.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Ewald, MD has received a total of $928.21 in payments from pharmaceutical and medical device companies, with $249.97 received in 2024. These payments were reported across 47 transactions from 14 companies. The most common payment nature is "Food and Beverage" ($928.21).
As a Medicare-enrolled provider, Ewald has provided services to 12,835 Medicare beneficiaries, totaling 15,182 services with total Medicare billing of $642,328. Data is available for 4 years (2020–2023), covering 115 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location N Chelmsford, MA
- Active Since 05/28/2006
- Last Updated 03/29/2013
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1639126311
Products in Payments
- LEQVIO (Drug) $219.35
- XARELTO (Drug) $110.60
- ELIQUIS (Drug) $64.76
- ENTRESTO (Drug) $56.54
- PRALUENT (Drug) $49.69
- CHANTIX (Drug) $48.22
- Repatha (Biological) $46.15
- Lexiscan (Drug) $44.08
- BRILINTA (Drug) $35.53
- FARXIGA (Drug) $34.08
- BRIDION (Drug) $28.97
- LifeVest (Device) $24.11
- GraftMaster coronary stent system (Device) $23.80
- VYNDAQEL (Drug) $23.69
- JARDIANCE (Drug) $21.96
- Asahi Standard guide wire (Device) $19.97
- VERQUVO (Drug) $19.78
- PRADAXA (Drug) $17.02
- KENGREAL 50MG/10ML L (Drug) $13.56
- Kerendia (Drug) $13.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in N Chelmsford
Benjamin Smith, Md, MD
Cardiovascular Disease — Payments: $3,613
Cardiovascular Disease $3,613
Kirk Macnaught, Md, MD
Cardiovascular Disease — Payments: $3,027
Cardiovascular Disease $3,027
Omar Ali, Md, MD
Cardiovascular Disease — Payments: $2,856
Cardiovascular Disease $2,856
Miret Ibrahim, Md, MD
Cardiovascular Disease — Payments: $1,148
Cardiovascular Disease $1,148
Harsh Sanchorawala, Md, MD
Cardiovascular Disease — Payments: $974.34
Cardiovascular Disease $974.34
Dr. Arash Tabaee, M.d, M.D
Cardiovascular Disease — Payments: $874.82
Cardiovascular Disease $874.82